Rearrangements of the PDGFRA (4q12), PDGFRB (5q32), and FGFR1 (8p11) genes are detected by fluorescence in situ hybridization (FISH).

Cytogenetic abnormalities commonly associated with myelodysplastic syndrome (MDS) are detected by fluorescence in situ hybridization (FISH). Probes for MECOM (3q26.2), 5q (5q-/-5/+5), 7q (7q-/-7), Cen 8 (+8), KMT2A (MLL)(11q23.3), ETV6 (12p13.2), TP53 (17p13.1), Cen 19 (+19), 20q (20q-) are included in the MDS Extended FISH Profile (Extended).

Cytogenetic abnormalities commonly associated with myelodysplastic syndrome (MDS) are detected by fluorescence in situ hybridization (FISH). Probes for 5q (5q-/-5/+5), 7q (7q-/-7), Cen 8 (+8), KMT2A (MLL)(11q23.3), 20q (20q-) are included in the MDS Standard FISH Profile.

Chromosomal gains, losses, deletions, inversions, or translocations commonly associated with various hematological disorders and solid tumors are detected by fluorescence in situ hybridization (FISH).

Chromosomal gains, losses, deletions, inversions, or translocations commonly associated with various hematological disorders and solid tumors are detected by chromosome analysis.

Includes COMPASS® consultation report, clinical pathology evaluation, blood morphology (up to 10 cytochemical stains), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.